Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,055 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Hoffmann-La Roche Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers

NCT01815827
View directory record Official record
Conditions
Healthy Volunteer
Interventions
inclacumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

NCT01323153
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
dalcetrapib, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
45 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Pensacola, Florida • Saginaw, Michigan • Saint Cloud, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 23, 2026, 10:11 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

NCT05548556
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
Placebo, RO7204239
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Orange, California • Aurora, Colorado • Fairway, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 10:11 AM EDT
Terminated Phase 1 Interventional

Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma

NCT00216437
View directory record Official record
Conditions
Cancer of Liver
Interventions
Capecitabine (Xeloda)
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 11, 2007 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers

NCT02074553
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ro542-4802/F03 (Reference), Ro542-4802/F07 (Test), Ro542-4802/F08 (Test), Ro542-4802/F14 (Test)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Jul 23, 2026, 10:11 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

NCT03287245
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Idasanutlin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Kansas City, Kansas • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Jul 23, 2026, 10:11 AM EDT
Terminated Phase 1 Interventional

Study of Intravenous RXDX-107 in Patients With Solid Tumors

NCT02548390
View directory record Official record
Conditions
Solid Tumor
Interventions
RXDX-107
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Sarasota, Florida • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

NCT00002374
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Stavudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

NCT04409262
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
Remdesivir, Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
38
States / cities
Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

NCT03174795
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
RO7079901, Meropenem
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
La Mesa, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

NCT00388986
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
GK Activator (2), Glyburide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Cypress, California • Honolulu, Hawaii • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants

NCT02717754
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Little Rock, Arkansas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

NCT00106574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
76
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 10:11 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Tiragolumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Hot Springs, Arkansas • Clovis, California • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 3 Interventional

A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

NCT01662869
View directory record Official record
Conditions
Gastric Cancer
Interventions
5-Fluoruracil, Folinic acid, Onartuzumab, Oxaliplatin, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Early Phase 1 Interventional

MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression

NCT00187941
View directory record Official record
Conditions
Transplantation, Renal, Immunosuppression
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Jul 23, 2026, 10:11 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT00642603
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin, irinotecan
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
76
States / cities
PARK Springs, Arizona • Sedona, Arizona • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

NCT04912869
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crovalimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 2 Interventional

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

NCT00413205
View directory record Official record
Conditions
Emphysema
Interventions
Placebo, RAR Gamma
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
44 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 10:11 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

NCT03456076
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Alectnib, Cisplatin, Vinorelbine, Gemcitabine, Pemetrexed, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

NCT00909597
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
pioglitazone, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
57
States / cities
Buena Park, California • Chino, California • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 10:11 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Obinutuzumab, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
14
States / cities
Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 1 Interventional

Study of Enfuvirtide in HIV-Positive Subjects

NCT00086710
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
Fuzeon
Drug
Lead sponsor
Trimeris
Industry
Eligibility
18 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

NCT01591850
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO5093151, atazanavir, ketoconazole, rifampicin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Merritt Island, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 10:11 AM EDT